Six drugs facing key patent expirations and potential generic entry from May to June 2022.

Abstract

A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.